Sponsored by
Two articles came out about this viral therapy that is approved in Japan for Glioblastoma.
The first is a phase 2 study reporting very promising results: the 1 year survival rate for recurrent Glioblastoma was 84.2%. 16 of 10 patients were alive at the one year mark. This treatment is injected directly into the tumor up to 6 times. As a result of this study, the treatment was approved in Japan with the name: DELYTACT . I have been trying to get it for patients here in the USA with no luck but will keep trying!
The second article is the phase 1/2 dose finding study which had less impressive results: the 1 year survival rate was 38% but they did have 2 long term survivors.